484 related articles for article (PubMed ID: 25568071)
1. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
Inturi B; Pujar GV; Purohit MN
Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
He X; Alian A; Ortiz de Montellano PR
Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
Lu XY; You QD; Chen YD
Mini Rev Med Chem; 2010 Mar; 10(3):181-92. PubMed ID: 20408801
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA.
McNeil MB; Dennison D; Shelton C; Flint L; Korkegian A; Parish T
Tuberculosis (Edinb); 2017 Dec; 107():133-136. PubMed ID: 29050761
[TBL] [Abstract][Full Text] [Related]
6. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
[TBL] [Abstract][Full Text] [Related]
7. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
[TBL] [Abstract][Full Text] [Related]
8. N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.
Guardia A; Gulten G; Fernandez R; Gómez J; Wang F; Convery M; Blanco D; Martínez M; Pérez-Herrán E; Alonso M; Ortega F; Rullás J; Calvo D; Mata L; Young R; Sacchettini JC; Mendoza-Losana A; Remuiñán M; Ballell Pages L; Castro-Pichel J
ChemMedChem; 2016 Apr; 11(7):687-701. PubMed ID: 26934341
[TBL] [Abstract][Full Text] [Related]
9. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.
Rao SP; Lakshminarayana SB; Kondreddi RR; Herve M; Camacho LR; Bifani P; Kalapala SK; Jiricek J; Ma NL; Tan BH; Ng SH; Nanjundappa M; Ravindran S; Seah PG; Thayalan P; Lim SH; Lee BH; Goh A; Barnes WS; Chen Z; Gagaring K; Chatterjee AK; Pethe K; Kuhen K; Walker J; Feng G; Babu S; Zhang L; Blasco F; Beer D; Weaver M; Dartois V; Glynne R; Dick T; Smith PW; Diagana TT; Manjunatha UH
Sci Transl Med; 2013 Dec; 5(214):214ra168. PubMed ID: 24307692
[TBL] [Abstract][Full Text] [Related]
10. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
Subba Rao G; Vijayakrishnan R; Kumar M
Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
Armstrong T; Lamont M; Lanne A; Alderwick LJ; Thomas NR
Bioorg Med Chem; 2020 Nov; 28(22):115744. PubMed ID: 33007556
[TBL] [Abstract][Full Text] [Related]
13. Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.
Encinas L; O'Keefe H; Neu M; Remuiñán MJ; Patel AM; Guardia A; Davie CP; Pérez-Macías N; Yang H; Convery MA; Messer JA; Pérez-Herrán E; Centrella PA; Alvarez-Gómez D; Clark MA; Huss S; O'Donovan GK; Ortega-Muro F; McDowell W; Castañeda P; Arico-Muendel CC; Pajk S; Rullás J; Angulo-Barturen I; Alvarez-Ruíz E; Mendoza-Losana A; Ballell Pages L; Castro-Pichel J; Evindar G
J Med Chem; 2014 Feb; 57(4):1276-88. PubMed ID: 24450589
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
[TBL] [Abstract][Full Text] [Related]
15. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates.
Rueda J; Realpe T; Mejia GI; Zapata E; Rozo JC; Ferro BE; Robledo J
Antimicrob Agents Chemother; 2015 Dec; 59(12):7805-10. PubMed ID: 26369965
[TBL] [Abstract][Full Text] [Related]
16. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
17. Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography.
Kamsri P; Hanwarinroj C; Phusi N; Pornprom T; Chayajarus K; Punkvang A; Suttipanta N; Srimanote P; Suttisintong K; Songsiriritthigul C; Saparpakorn P; Hannongbua S; Rattanabunyong S; Seetaha S; Choowongkomon K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Chen Z; Zhu W; Blood RA; Takebayashi Y; Hinchliffe P; Mulholland AJ; Spencer J; Pungpo P
J Chem Inf Model; 2020 Jan; 60(1):226-234. PubMed ID: 31820972
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
Parikh SL; Xiao G; Tonge PJ
Biochemistry; 2000 Jul; 39(26):7645-50. PubMed ID: 10869170
[TBL] [Abstract][Full Text] [Related]
19. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
[TBL] [Abstract][Full Text] [Related]
20. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
